Upstream Bio Revenue and Competitors

Location

#6522

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Upstream Bio's estimated annual revenue is currently $3.3M per year.(i)
  • Upstream Bio's estimated revenue per employee is $77,500
  • Upstream Bio's total funding is $400M.

Employee Data

  • Upstream Bio has 43 Employees.(i)
  • Upstream Bio grew their employee count by 16% last year.

Upstream Bio's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Co-Founder & Founding President R&DReveal Email/Phone
3
CEOReveal Email/Phone
4
Chief Medical Officer and Head Research and DevelopmentReveal Email/Phone
5
Chief Business OfficerReveal Email/Phone
6
Chief Operating OfficerReveal Email/Phone
7
Head Translational ResearchReveal Email/Phone
8
Head Technical OperationsReveal Email/Phone
9
VP, Head Clinical DevelopmentReveal Email/Phone
10
SVP Regulatory Affairs and QualityReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Upstream Bio?

At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones.

keywords:N/A

$400M

Total Funding

43

Number of Employees

$3.3M

Revenue (est)

16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M4310%N/A
#2
$3.5M43-9%N/A
#3
$6.3M44-6%N/A
#4
$9.5M4410%N/A
#5
$11.6M45-4%N/A